AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUL 12 min read$CLYM

Climb Bio, Inc. (CLYM): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001768446 0001768446 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,

Original reporting
SEC EDGAR 8-K
Published Jul 1, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$CLYM
Neutral
medium confidence
Mentioned
$CLYM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CLYMNeutralLow
01

Why it matters

The only new, decision-relevant details are the resignation of Andrew Levin and the immediate election of Breanna O’Reilly, plus her director compensation structure and option grant terms.

02

Market read

Updates CLYM’s board composition and director compensation; no clinical, regulatory, or financial guidance is provided.

03

What to watch

Traders may overreact to the option strike ($13.36) despite it being set to the closing price on the grant date, not a forward-looking valuation signal.

Relevance 6/10Novelty 5/10Timing: filed July 1, 2026 (after-hours/late day) following June 29 board actions

Background

This is an SEC Form 8-K (Item 5.02) reporting director/officer changes and compensatory arrangements.

Company-level read

Ticker impact

$CLYMNeutralMedium confidence
Context

Climb Bio disclosed a director resignation and the immediate election of Breanna O’Reilly, including a 70,284-share option grant at $13.36.

Expected impact

Low probability of a sustained move; any reaction likely limited to governance/compensation sentiment.

Evidence & confidence

The filing is a routine 8-K (Item 5.02) with no operational or financial guidance, but it is a fresh, company-specific datapoint (new director + option terms).

Market effects

Sector

Minimal; governance/compensation changes at a single biotech typically do not reset sector risk premia.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The director change could be interpreted as internal reshuffling ahead of upcoming catalysts, but the filing provides no explicit link to strategy or trials.

Key entities

  • company
    Climb Bio, Inc.

    Nasdaq-listed biotech issuer filing the 8-K reporting board changes and director compensation.

  • person
    Andrew Levin

    Resigned as a director effective immediately on June 29, 2026.

  • person
    Breanna O’Reilly, Ph.D.

    Elected as a director effective immediately on June 29, 2026; receives director compensation and an option grant.

Read at source← All news

Related articles

SEP 3
$CLYMMedAI 8/10

Climb Bio Shares Rise On CLYM116 Data Supporting Every-12-Week Dosing

Climb Bio (CLYM) reported positive Phase 1 data for CLYM116, showing prolonged half-life and durable suppression of targets, supporting every-12-week dosing. The treatment was well-tolerated. CLYM116 is being advanced in the Phase 2 NAVIGATE-2 trial for IgA nephropathy, with initial data expected in 2027. The company reported Q2 2026 net income of $1.9M and $239.2M in cash. CLYM stock rose 1.55% to $15.05 on Wednesday.

rttnews.com2 min
SEP 3
$CLYMMedAI 8/10

Why is Climb Bio stock sliding today?

Climb Bio (CLYM) stock fell 7% to $14.00 in pre-market trading after releasing Phase 1 clinical data for CLYM116, showing near-complete APRIL protein suppression and sustained IgA reductions. The decline follows a 'buy the rumor, sell the news' pattern, with investors taking profits after the data release. The company's Phase 2 trial data is not expected until 2027, contributing to the pullback. The broader market showed modest gains, with the S&P 500, Dow Jones, and Nasdaq up 0.3%, 0.6%, and 0.

investing.com2 min
SEP 3
$CLYMMedAI 8/10

Climb Bio, Inc.: Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

Climb Bio (CLYM) reported positive Phase 1 data for CLYM116, showing a 29-day half-life, 90% APRIL suppression, and 60-75% IgA suppression. The drug was well-tolerated. Phase 2 trial data is expected in H1 2027, with Phase 3 initiation planned for 2027. The company will host a webcast on September 3.

finanznachrichten.de2 min
SEP 3
$CLYMHighAI 8/10

Climb Bio stock surges 17% on positive drug trial results

Climb Bio, Inc. (CLYM) shares rose 17% after reporting positive Phase 1 trial results for CLYM116, its anti-APRIL monoclonal antibody. The drug showed near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression, with a half-life of 29 days. The trial enrolled 46 subjects and reported no serious adverse events. The company plans to present additional data in Q4 2026 and anticipates Phase 2 trial results in H1 2027.

investing.com2 min
AUG 6
$CLYMMed

Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2

SEC EDGAR 8-K6 min
OCT 3
$7203.TMed

Chinese auto show debuts in Argentina as sales surge

Argentina hosts its first Chinese auto show as Chinese brands gain market share, accounting for 10% of August sales. BYD 002594.SZ is now the ninth best-selling brand. Over 20 Chinese brands, including Geely 0175.HK and Chery 9973.HK, were displayed. Toyota 7203.T plans a $1.34B EV plant. Tesla may enter Argentina. Car sales fell 13% YoY due to market adjustment and high interest rates.

manilatimes.net2 min